In osteolytic bone metastases, TGF-β released during bone resorption enhances tumor growth and furthers bone degradation; thus, inhibiting TGF-β can disrupt this cycle, reducing tumor burden and bone destruction [39]. This evidence concerns the gene TGFB1 and neoplasm.